The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
Capital infusion to accelerate Earendil’s R&D platform
The endorsement follows overwhelming support for the share swap preceding the merger,
Nearly 12 million people are estimated to be living with glaucoma, making the country one of the worst affected globally
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
Subscribe To Our Newsletter & Stay Updated
